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Background: Ticagrelor (TIC), a novel anti-platelet agent, reduces CV events including mortality in ACS. It may increase local adenosine 
concentrations and bradycardic events.
Methods: 2908 pts in the PLATO study comparing TIC and clopidogrel (CLOP) had 7-day continuous ECG (cECG) monitoring after randomization 
and at Day 30 to evaluate 1) differences in arrhythmias detected on cECG and 2) if arrhythmias were associated with clinical adverse events.
Results: At randomization, more pts treated with TIC vs. CLOP had ventricular pauses >3s (5.8 vs 3.6%, p=0.01) and >5s (2.0 vs 1.2%, p=0.10). 
Among pts with >5 episodes of pauses (n=33), the greatest excess of pauses in pts receiving TIC occurred at night (Figure). At 30d, bradyarrhythmias 
occurred less frequently and were more similar between treatments (2.1 v. 1.7% for >3s; 0.8 v. 0.6% for >5s pauses). Most pauses were SA nodal 
(66%). Among pts with pauses >3s, there were no differences in arrhythmic adverse events that occurred during cECG (19.1 v 22.6%) or during the 
entire 1-yr study (25.8 vs 25.8%), including syncope and pacemaker placement. There were also no differences in VT or SVT, though fewer pts on TIC 
had sudden cardiac death.
Conclusion: In PLATO, more pts on TIC than CLOP had ventricular pauses, which were predominantly asymptomatic, often SA nodal, and 
more common early after ACS and at night. However, there were no apparent clinical consequences related to the excess in ventricular pauses.
